BRAF gene mutations are rare events in gastroenteropancreatic neuroendocrine tumors

American Journal of Clinical Pathology

Volumn 123, Issue 2, 2005, Pages 256-260

  Tannapfel, Andrea ^a   Vomschloss, Susanne ^a   Karhoff, Dorothee ^b   Markwarth, Anett ^a   Hengge, Ulrich R ^c   Wittekind, Christian ^a   Arnold, Rudolf ^b   Hörsch, Dieter ^b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

BRAF; Immunohistochemistry; K ras 2; Mutation; Neuroendocrine tumor

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RAF PROTEIN; RAS PROTEIN;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; GENE FREQUENCY; GENE LOCATION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MUTATIONAL ANALYSIS; NEUROENDOCRINE TUMOR; ONCOGENE K RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

EID: 13244284719     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/YQBR9C05RU4DD3RN     Document Type: Article

References (23)

1. Solcia E, Klöppel G, Sobin LH, eds. Histological Typing of Endocrine Tumours. 2nd ed. Berlin, Germany: Springer; 2000. World Health Organization International Histological Classification of Tumours.
2. Rindi G, Capella C, Solcia E. Cell biology, clinicopathological profile, and classification of gastro-enteropancreatic endocrine tumors. J Mol Med. 1998;76:413-420.
3. Lubomierski N, Kersting M, Bert T, et al. Tumor suppressor genes in the 9p21 gene cluster are selective targets of inactivation in neuroendocrine gastroenteropancreatic tumors. Cancer Res. 2001;61:5905-5910.
4. Tomassetti P, Migliori M, Lalli S, et al. Epidemiology, clinical features and diagnosis of gastroenteropancreatic endocrine tumours. Ann Oncol. 2001;12(suppl 2):S95-S99.
5. Paraskevakou H, Saetta A, Skandalis K, et al. Morphological-histochemical study of intestinal carcinoids and K-ras mutation analysis in appendiceal carcinoids. Pathol Oncol Res. 1999;5:205-210.
6. Couce ME, Bautista D, Costa J, et al. Analysis of K-ras, N-ras, H-ras, and p53 in lung neuroendocrine neoplasms. Diagn Mol Pathol. 1999;8:71-79.
7. Harvey M, Vogel H, Lee E, et al. Mice deficient in both p53 and Rb develop tumors primarily of endocrine origin. Cancer Res. 1995;55:1146-1151.
8. Rul W, Zugasti O, Roux P, et al. Activation of ERK, controlled by Racl and Cdc42 via Akt, is required for anoikis. Ann N Y Acad Sci. 2002;973:145-148.
9. Peyssonnaux C, Eychene A. The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell. 2001;93:53-62.
10. Hagemann C, Rapp UR. Isotype-specific functions of Raf kinases. Exp Cell Res. 1999;253:34-46.
11. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954.
12. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet. 2003;33:19-20.
13. Fukushima T, Suzuki S, Mashiko M, et al. BRAF mutations in papillary carcinomas of the thyroid. Oncogene. 2003;22:6455-6457.
14. Soares P, Trovisco V, Rocha AS, et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene. 2003;22:4578-4580.
15. Lee SH, Lee JW, Soung YH, et al. BRAF and KRAS mutations in stomach cancer. Oncogene. 2003;22:6942-6945.
16. Naoki K, Chen TH, Richards WG, et al. Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res. 2002;62:7001-7003.
17. Yuen ST, Davies H, Chan TL, et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res. 2002;62:6451-6455.
18. Sommerer F, Hengge U, Markwarth A, et al. Mutations of the BRAF and ras are rare events in germ cell tumours. Int J Cancer. 2004;113:329-335.
19. Brose MS, Volpe P, Feldman M, et al. BRAF and ras mutations in human lung cancer and melanoma. Cancer Res. 2002;62:6997-7000.
20. Weber A, Langhanki L, Sommerer F, et al. Mutations of the BRAF gene in squamous cell carcinoma of the head and neck. Oncogene. 2003;22:4757-4759.
21. Singer G, Oldt R III, Cohen Y, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst. 2003;95:484-486.
22. Rajagopalan H, Bardelli A, Lengauer C, et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature. 2002;418:934.
23. Hakimi MA, Bochar DA, Chenoweth J, et al. A core-BRAF35 complex containing histone deacetylase mediates repression of neuronal-specific genes. Proc Natl Acad Sci U S A. 2002;99:7420-7425.